How Renew31 is said to work, and where the documents stop

Part A

What happens, as far as the documents go

A page with this title sets an expectation: that a reader will be told what the gummy does. This one walks as far as the documents go and stops.

Those five steps are a complete description of the product and no description of a mechanism. That is not a violation: a dietary supplement is not required to publish one, and an invented mechanism would be worse than none. Two kinds of silence are worth separating, though. A manufacturer saying nothing about how a product works is lawful and common. A federal agency having published nothing about an ingredient at all is something else. Six of the ten things this label declares are addressed by no federal health agency this desk could open. That is not a verdict on them. It is the state of what could be read.

Part B

The panel the seller publishes under this heading

The sales material supplied with this stock has a section headed how it works. Reproduced below as supplied, because the gap between a heading and its contents is the finding.

It is a numbered strip. What it describes is when to take the gummy, with what, and how long before a meal: the dosing instruction cut into pieces. No step describes a route from the gummy to an outcome, or cites anything.

This page is not calling that dishonest. The steps agree with the printed directions. The problem is expectation: a reader who has read a panel headed how it works may reasonably believe they have been told how the product works, when what they have been told is when to take it.

Supplied, not verified

The seller's how-it-works panel, as supplied

Reproduced from the stock pack supplied with this product; not verified here.

Part C

The one studied dose range that touches this label

Chicory root inulin is first in the printed order, so it is the heaviest of the nine, and the only blend member for which a federal source publishes a studied intake. The endpoint is not the one a reader expects.

FDA’s 2018 review of certain non-digestible carbohydrates puts the studied intake for inulin-type fructans at “3 to 40 g/day” ^FDA. The entire blend is 430 mg, or 0.43 g, so 14% of the bottom of that range, whose floor is about 7 times the whole blend and whose top is about 93 times. Inulin alone cannot be all of the blend.

The sentence FDA published is this: “The strength of the evidence supports that inulin-type fructans extracted from chicory root or extracted inulin-type fructans from all sources, as well as synthetic inulin-type fructans, have a beneficial physiological effect on bone mineral density and absorption of calcium.” ^FDA Bone and calcium. The product is sold as gut and inner-nutrition support, and the recognised federal effect attached to its heaviest ingredient is about neither.

A studied intake range is an intake used in research for one endpoint, not a minimum anybody must reach, and falling short of it is not a finding of no effect.

Part D

The probiotic half, and the sentences that govern it

The other half of this product is one organism on one line. There is more federal writing about probiotics in general than about anything else here, and almost none of it can be pointed at this bottle.

NIH ODS describes the market: “Many probiotic supplements contain 1 to 10 billion CFU per dose, but some products contain 50 billion CFU or more.” ^{NIH ODS} And then, in the same fact sheet, immediately afterwards: “However, products with higher CFU counts are not necessarily more effective than products with a lower CFU count.” ^{NIH ODS} Both halves travel together on this site. A band describing what products contain is not a threshold and not an effective dose.

NCCIH states the underlying gap more bluntly, and this sentence decides what a mechanism page can say: “We also don’t know how much of the probiotic people would have to take or who would be most likely to benefit.” ^NCCIH Then the fact that closes it for this organism. No federal source this desk opened publishes any dose, finding or safety statement for Bacillus coagulans. The species appears in no federal source this desk opened. NIH ODS and NCCIH name the genus Bacillus in passing lists and nothing more: no dose, no finding, no safety statement and no interaction for this organism.

Part E

Three questions behind the phrase, and where each stops

The heading on this page is three questions wearing one coat, and only one of them is unanswerable.

That third tab decides the page. Assembling four paragraphs about what lion’s mane is traditionally held to do and presenting them as an account of this gummy would be writing fiction with citations attached, and for six of the ten there is no federal paragraph to borrow in the first place.

What would change this page is short: a published trial on the finished formula, a mechanism statement with something behind it, or an individual weight printed inside the blend. None of the three was supplied.